3-(3-Bromoimidazo[1,2-b]pyridazin-6-ylamino)propan-1-ol | 1034621-87-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-(3-Bromoimidazo[1,2-b]pyridazin-6-ylamino)propan-1-ol
• 英文别名: 3-[(3-bromoimidazo[1,2-b]pyridazin-6-yl)amino]propan-1-ol
• CAS: 1034621-87-8
• 化学式: C₉H₁₁BrN₄O
• 分子量: 271.117
• InChiKey: BPVHPJVFWJYXJY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  62.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(3-Bromoimidazo[1,2-b]pyridazin-6-ylamino)propan-1-ol 在 4-二甲氨基吡啶 、 四丁基氟化铵 、 sodium hydride 、 三乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 3: Exploration of effective compounds in arthritis models

  摘要：

  We have discovered imidazo[1,2-b]pyridazine derivatives that show suppressive activity of inflammation in arthritis models. We optimized the substructures of imidazo[1,2-b] pyridazine derivatives to combine potent IKK beta inhibitory activity, TNF alpha inhibitory activity in vivo and excellent pharmacokinetics. The compound we have acquired, which had both potent activities and good pharmacokinetic profiles based on improved physicochemical properties, demonstrated efficacy on collagen-induced arthritis models in mice and rats. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.05.115
• 作为产物：
  描述：

  3-溴-6-氯咪唑并[1,2-b]哒嗪 、 3-氨基-1-丙醇 以 N-甲基吡咯烷酮 为溶剂， 以99%的产率得到3-(3-Bromoimidazo[1,2-b]pyridazin-6-ylamino)propan-1-ol
  参考文献：
  名称：

  Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 3: Exploration of effective compounds in arthritis models

  摘要：

  We have discovered imidazo[1,2-b]pyridazine derivatives that show suppressive activity of inflammation in arthritis models. We optimized the substructures of imidazo[1,2-b] pyridazine derivatives to combine potent IKK beta inhibitory activity, TNF alpha inhibitory activity in vivo and excellent pharmacokinetics. The compound we have acquired, which had both potent activities and good pharmacokinetic profiles based on improved physicochemical properties, demonstrated efficacy on collagen-induced arthritis models in mice and rats. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.05.115

文献信息

• 6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS
  申请人：CHEN Hwang-Hsing

  公开号：US20080153813A1

  公开（公告）日：2008-06-26

  Methods for using 6-aminoimidazo[1,2-b]pyridazine analogs are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of 6-aminoimidazo[1,2-b]pyridazine analogs, are disclosed herein.

  本文披露了使用6-氨基咪唑并[1,2-b]吡啶嗪类似物治疗rho激酶介导的疾病或rho激酶介导的症状的方法，包括控制眼压和治疗青光眼。本文还披露了用于治疗眼部疾病如青光眼，并且对控制眼压有益的眼科药物组合物，该组合物包括有效量的6-氨基咪唑并[1,2-b]吡啶嗪类似物。
• 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
  申请人：Alcon Research, Ltd.

  公开号：US07820670B2

  公开（公告）日：2010-10-26

  Methods for using 6-aminoimidazo[1,2-b]pyridazine analogs are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of 6-aminoimidazo[1,2-b]pyridazine analogs, are disclosed herein.

  本文披露了使用6-氨基咪唑[1,2-b]吡嗪类似物治疗rho激酶介导的疾病或rho激酶介导的病症的方法，包括控制眼内压和治疗青光眼。本文还披露了眼科制药组合物，对于治疗眼部疾病如青光眼，以及控制眼内压具有额外的用途，该组合物包括6-氨基咪唑[1,2-b]吡嗪类似物的有效量。
• US7820670B2
  申请人：——

  公开号：US7820670B2

  公开（公告）日：2010-10-26
• [EN] 6-AMINOIMIDAZO[1,2-B]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION<br/>[FR] ANALOGUES DE LA 6-AMINOIMIDAZO[1,2-B]PYRIDAZINE EN TANT QU'INHIBITEURS DE LA RHO KINASE POUR LE TRAITEMENT DU GLAUCOME ET DE L'HYPERTENSION OCULAIRE
  申请人：ALCON RES LTD

  公开号：WO2008079880A1

  公开（公告）日：2008-07-03

  [EN] Methods for using 6-aminoimidazo[1,2-b]pyridazine analogs are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of 6-aminoimidazo[1,2-b]pyridazine analogs, are disclosed herein.
  [FR] La présente invention concerne des procédés d'utilisation d'analogues de la 6-aminoimidazo[1,2-b]pyridazine pour le traitement de maladies ou d'affections induites par la Rho kinase, y compris la lutte contre la pression intraoculaire et le traitement du glaucome. L'invention concerne des compositions pharmaceutiques ophtalmiques utilisables pour le traitement de maladies des yeux telles que le glaucome et utilisables en outre pour lutter contre la pression intraoculaire, les compositions comprenant une quantité efficace d'analogues de la 6-aminoimidazo[1,2-b]pyridazine.
• Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 3: Exploration of effective compounds in arthritis models
  作者：Hiroki Shimizu、Tomonori Yamasaki、Yoshiyuki Yoneda、Fumihito Muro、Tomoaki Hamada、Takanori Yasukochi、Shinji Tanaka、Tadashi Toki、Mika Yokoyama、Kaoru Morishita、Shin Iimura

  DOI：10.1016/j.bmcl.2011.05.115

  日期：2011.8

  We have discovered imidazo[1,2-b]pyridazine derivatives that show suppressive activity of inflammation in arthritis models. We optimized the substructures of imidazo[1,2-b] pyridazine derivatives to combine potent IKK beta inhibitory activity, TNF alpha inhibitory activity in vivo and excellent pharmacokinetics. The compound we have acquired, which had both potent activities and good pharmacokinetic profiles based on improved physicochemical properties, demonstrated efficacy on collagen-induced arthritis models in mice and rats. (C) 2011 Elsevier Ltd. All rights reserved.